Dogwood Therapeutics, Inc. (DWTX) - Total Assets
Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) holds total assets worth $91.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Dogwood Therapeutics, Inc. service its debt to assess how comfortably operating cash covers total debt obligations.
Dogwood Therapeutics, Inc. - Total Assets Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See Dogwood Therapeutics, Inc. net assets for net asset value and shareholders' equity analysis.
Dogwood Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Dogwood Therapeutics, Inc.'s total assets of $91.99 Million consist of 17.5% current assets and 82.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $65.71 Million | 69.7% |
| Goodwill | $11.81 Million | 12.5% |
Asset Composition Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Dogwood Therapeutics, Inc. worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dogwood Therapeutics, Inc.'s current assets represent 17.5% of total assets in 2024, a decrease from 64.3% in 2018.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, down from 45.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 69.7% of total assets.
Dogwood Therapeutics, Inc. Competitors by Total Assets
Key competitors of Dogwood Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Dogwood Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.49 | 1.71 | 20.55 |
| Quick Ratio | 4.49 | 1.71 | 20.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.06 Million | $949.43K | $29.94 Million |
Dogwood Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Dogwood Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | 2164.1% |
| Total Assets | $94.31 Million |
| Market Capitalization | $48.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dogwood Therapeutics, Inc.'s assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dogwood Therapeutics, Inc.'s assets grew by 2164.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual total assets of Dogwood Therapeutics, Inc. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $94.31 Million | +2164.06% |
| 2023-12-31 | $4.17 Million | -50.23% |
| 2022-12-31 | $8.37 Million | -46.95% |
| 2021-12-31 | $15.78 Million | -49.87% |
| 2020-12-31 | $31.47 Million | +9862.88% |
| 2019-12-31 | $315.90K | +379.11% |
| 2018-12-31 | $65.94K | -- |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more